Regeneron Sues Sandoz in Federal Court to Block Eylea Biosimilar

In its legal complaint, filed in the District Court for New Jersey, Regeneron alleges that Sandoz failed to provide it with relevant information required under the Biologics Price Competition and Innovation Act.

Scroll to Top